Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma.

ABSTRACT: Advances in molecular cell biology over the last decade have clarified the mechanisms involved in cancer growth, invasion, and metastasis, and enabled the development of molecular-targeted agents. To date, sorafenib is the only molecular-targeted agent whose survival benefit has been demonstrated in two global phase III randomized controlled trials, and has been approved worldwide. Phase III clinical trials of other molecular targeted agents comparing them with sorafenib as first-line treatment agents are ongoing. Those agents target the vascular endothelial growth factor, platelet-derived growth factor receptors, as well as target the epidermal growth factor receptor, insulin-like growth factor receptor and mammalian target of rapamycin, in addition to other molecules targeting other comp

SUBMITTER: Kudo M 

PROVIDER: S-EPMC3496878 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature